Veterinary Students Symposium Showcases Veterinary Expertise And Highlights Want For Continued Innovation In Advancing Animal And Human Well being

DULUTH, Ga., August 6, 2020 / PRNewswire / – More than 500 U.S. veterinary students, animal health researchers and executives from three dozen top veterinary schools practically came this week to the Veterinary Summer Scholars Symposium and the presentation of the annual Boehringer Ingelheim Research Awards for joint veterinarians and veterinary students.

This annual scientific colloquium – usually conducted in person – features research from veterinary students doing summer research internships. It offers students of the Boehringer Ingelheim Veterinary Scholars Program the opportunity to present and discuss research results. Veterinary scientists also have the opportunity to network with one another and with mentors from academia, industry and government.

The Boehringer Ingelheim Veterinary Scholars Program was established more than 30 years ago to introduce first and second year veterinary medicine students to biomedical research. Almost 4,000 students have received scholarships from Boehringer Ingelheim to do research since the program began. Further information is available at

At each participating school, the Boehringer Ingelheim Veterinary Scholars receive a mentor and a laboratory. Every scientist carries out a hypothesis-driven research project. The research project is usually carried out over a period of 10 to 12 weeks in the summer, with the students presenting their work at the end. This year, the 35 participating schools quickly deployed alternative plans to comply with COVID-19 security measures. Some offered laboratory projects to students in a way that provided social distancing and related protection. Others focused student research on data analysis projects that could be done outside of the company.

“We hope that something good can come of the many lessons we learned during this year’s pandemic so that we can better identify and treat or even prevent the next pandemic or major threat to human and animal health,” said he Caroline Belmont, Head of US Animal Health Innovation at Boehringer Ingelheim. “Recent events have shown the importance of innovation and collaboration to meet unmet human and animal health needs. We look forward to the many future contributions that veterinary students and researchers today will make to these Efforts to advance. “

Students from more than three dozen veterinary schools participating in the Veterinary Scholars Program can apply for two annual awards: the Boehringer Ingelheim Veterinary Graduate Award and the Veterinary Research Scholar Award. Winners will receive cash prizes and a scholarship to attend the annual Veterinary Scholars Symposium to receive their awards and present their research.

The 2020 Boehringer Ingelheim Veterinary Graduate Award was presented to Dr. Sara Hamman Osum, a PhD student completing her Ph.D. in the Graduate Program in Comparative and Molecular Biosciences at the University of Minnesota College of Veterinary Medicine.

Dr. Osums Ph.D. Research focused on developing and characterizing the first pig model of neurofibromatosis type 1 (NF1), a devastating neurological disease for which there is no cure. Before joining the DVM / PhD program at the University of MinnesotaShe spent four years as a research fellow, studying tolerance and autoimmunity models, and promoting her interest in advancing animal welfare by developing improved animal models for preclinical research. Dr. Osum received her doctorate in veterinary medicine from the University of Minnesota in 2016 and her Bachelor of Science in Biology from the University of California at Santa Cruz, California, in 2008.

The Boehringer Ingelheim Veterinary Graduate Award promotes research in the veterinary life sciences. It recognizes qualified veterinarians who have completed a PhD or are about to complete. Program or are in the final years of their training in veterinary pathology, medicine, surgery, radiology / imaging, or laboratory animal medicine. Recipients receive a fee and are invited to present their research results at the annual Veterinary Scholars Symposium.

The recipient of the Boehringer Ingelheim Veterinary Research Scholar Award 2020 is Megan Fahey, a DVM and Ph.D. Student at Cornell University College of Veterinary Medicine. Fahey has pursued a career as a veterinary clinician and her research interests have focused on zoonosis, virology, and immunology. Her work in the Boehringer Ingelheim Veterinary Scholars Program included research into the use of mesenchymal stem cells to prevent or reduce degeneration in disc disease.

Caroline Schlaeppi Fisher, from North Carolina State University College of Veterinary Medicine, received an Honorable Mention, 2020 Boehringer Ingelheim Veterinary Research Scholar. This distinction recognizes her work in evaluating the effectiveness of the reuse and sterilization of certain devices used in veterinary surgery to help develop evidence-based guidelines for the reuse of such devices.

Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that people are also healthier when animals are healthy. Our 10,000 employees worldwide are committed to creating value through innovation and thus improving the wellbeing of both.

The focus of our actions is on respect for animals, people and the environment. We develop solutions and offer services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protecting our communities from life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is with sales of $ 4.5 billion ((4 billion euros) in 2019 and presence in more than 150 countries.

Boehringer Ingelheim Animal Health is in The United Stateswith more than 3,100 employees in places that belong to Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. Further information is available at, or

Boehringer Ingelheim
The production of new and better drugs for humans and animals is the focus of our actions. Our mission is to create breakthrough therapies that change lives. Boehringer Ingelheim has been independent and family-owned since it was founded in 1885. We have the freedom to pursue our long-term vision, predictively identify the health challenges of the future, and target those areas where we can do our best.

As the world’s leading, research-oriented pharmaceutical company, more than 51,000 employees create value every day through innovation for our three business areas: human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

In 2019 Boehringer Ingelheim achieved net sales of $ 21.3 billion ((19 billion euros). Our significant investment of over $ 3.9 billion ((3.5 billion euros) in research and development drives innovation and enables the next generation of drugs that save lives and improve the quality of life.

We’re realizing more science opportunities by harnessing the power of partnership and the diversity of experts across the life science community. By working together, we are accelerating the delivery of the next medical breakthrough that will change the lives of patients now and for generations to come.

You can find more information about Boehringer Ingelheim at or in our annual report:

SOURCE Boehringer Ingelheim Animal Health USA Inc.

similar links

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.